Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
48.86 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 47.58 - 70.935 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 48.86 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
98.8B | 2.02B | - | 45.01B | 8.03B | 3.97 | 12.31 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 47.94 | 49.56 | 47.615 | 48.82 | 10,869,829 | 0.92 | 1.92% |
1 Month | 53.39 | 54.475 | 47.615 | 50.20 | 11,069,328 | -4.53 | -8.48% |
3 Months | 48.86 | 55.035 | 47.58 | 51.00 | 15,544,520 | 0.00 | 0.00% |
6 Months | 56.02 | 56.77 | 47.58 | 50.91 | 15,483,656 | -7.16 | -12.78% |
1 Year | 70.68 | 70.935 | 47.58 | 55.26 | 12,734,367 | -21.82 | -30.87% |
3 Years | 66.00 | 81.435 | 47.58 | 63.86 | 11,513,311 | -17.14 | -25.97% |
5 Years | 45.05 | 81.435 | 41.19 | 61.00 | 12,268,620 | 3.81 | 8.46% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |